Form 4 for STRO SUTRO BIOPHARMA, INC.
Accepted 2025-12-16 00:00:00 ET · period of report 2025-12-12 · accession 0001872398-25-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-16 | 2025-12-12 | STRO | Chung Jane | CEO, Dir | F - Tax | $8.02 | -894 | 13.9K | -6% | -$7,170 |
| D | 2025-12-16 | 2025-12-12 | STRO | Chung Jane | CEO, Dir | M - OptEx | $0.00 | +2,500 | 14.8K | +20% | $0 |
| D | 2025-12-16 | 2025-12-12 | STRO | Chung Jane | CEO, Dir | M - OptEx | $0.00 | -2,500 | 5,000 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | F | D | 894 | $8.02 | 13,891 | D | — | — | (F1) Represents the number of shares of Common Stock that have been withheld by the Issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of RSUs; does not represent a sale by the reporting person. |
| 2 | Common | Common Stock | 2025-12-12 | M | A | 2,500 | $0.00 | 14,785 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit (RSU) | 2025-12-12 | M | D | 2,500 | $0.00 | 5,000 | D | — · — to 2027-12-01 | 2,500 Common Stock | (F2) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. (F3) The RSU award vested or vests as to 1/4th of the total award annually, subject to continued service through each vesting date, with the first tranche vested on December 1, 2024. The reported transaction represents the deferred vesting and settlement of a tranche of this award pursuant to the terms of the reporting person's award agreement with the Issuer. |